BusinessImmuron Enrols First Patients in Clinical Study of IMM-529 for Treatment of Clostridium Difficile Infection (CDI)By Nasdaq OMXJan 31, 2018, 2:30 PM UTC
BusinessSummit Enters Into Licence and Commercialisation Agreement With Eurofarma for Latin American Rights to Ridinilazole, Summit’s Precision Antibiotic in Development for the Treatment of CDIBy Nasdaq OMXDec 21, 2017, 7:00 AM UTC
BusinessVan Leeuwenhoeck Institute Updates Immuron Research CoverageBy Nasdaq OMXNov 22, 2017, 2:00 PM UTC
BusinessSummit Highlights Microbiome Preservation During Ridinilazole Treatment in Exploratory Phase 2 Clinical Trial at ID Week 2017By Nasdaq OMXOct 9, 2017, 11:00 AM UTC
BusinessSummit Therapeutics Reports Financial Results for the First Quarter Ended 30 April 2017 and Operational ProgressBy Nasdaq OMXJun 14, 2017, 11:00 AM UTC
BusinessPhase 2 CoDIFy Trial Results Published in Lancet Infectious Diseases With Data Showing Summit’s Ridinilazole Achieved Statistical Superiority over Vancomycin in the Treatment of C. Difficile InfectionBy Nasdaq OMXApr 28, 2017, 10:30 PM UTC
